@article{1f37f23402314080871864adb4196706,
title = "Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States",
abstract = "Background: Outcomes data regarding advanced synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are limited, consisting primarily of retrospective series and post hoc analyses of clinical trials. Methods: In this multi-center retrospective study, data were abstracted from the medical records of 350 patients from nine sarcoma centers throughout the United States and combined into a registry. Patients with advanced/unresectable or metastatic SS (n = 249) or MRCL (n = 101) who received first-line systemic anticancer therapy and had records of tumor imaging were included. Overall survival (OS), time to next treatment, time to distant metastasis, and progression-free survival (PFS) were evaluated using the Kaplan-Meier method and Cox regression. Results: At start of first-line systemic anticancer therapy, 92.4% of patients with SS and 91.1% of patients with MRCL had metastatic lesions. However, 74.7% of patients with SS and 72.3% of patients with MRCL had ≥2 lines of systemic therapy. Median OS and median PFS from first-line therapy for SS was 24.7 months (95% CI, 20.9-29.4) and 7.5 months, respectively (95% CI, 6.4-8.4). Median OS and median PFS from start of first-line therapy for MRCL was 29.9 months (95% CI, 27-44.6) and 8.9 months (95% CI 4.5-12.0). Conclusions: To the best of our knowledge, this is the largest retrospective study of patients with SS and MRCL. It provides an analysis of real-world clinical outcomes among patients treated at major sarcoma cancer centers and could inform treatment decisions and design of clinical trials. In general, the survival outcomes for this selected population appear more favorable than in published literature.",
keywords = "database, medical records, myxoid, neoplasms, registries, sarcoma, synovial",
author = "Pollack, {Seth M.} and Neeta Somaiah and Araujo, {Dejka M.} and Mihaela Druta and {Van Tine}, {Brian A.} and Burgess, {Melissa A.} and Chawla, {Sant P.} and Mahesh Seetharam and Okuno, {Scott H.} and Chet Bohac and Michael Chen and Sergey Yurasov and Steven Attia",
note = "Funding Information: Chet Bohac, Michael Chen, and Sergey Yurasov are current or former employees of Immune Design Corp. Seth Pollack has received honoraria from Seattle Genetics, Bayer, Tempus, Daiichi Sankyo, and Blueprint, and grants and research funding from Merck, EMD Sereno, Incyte, Presage, Janssen, Oncosec, and Juno Therapeutics. Mihaela Druta has received consulting fees from Immune Design Corp. Brian Van Tine reports basic science grant funding from Pfizer, Tracon, and Merck; consulting fees from Epizyme, Lilly, CytRx, Janssen, Immune Design, Daiichi Sankyo, Plexxikon, and Adaptimmune; speaking fees from Caris, Janssen, and Lilly; and travel support from Lilly, GSK, and Adaptimmune. Sant Chawla has received honoraria and research funding from Immune Design Corp., Amgen, CytRx Corporation, GlaxoSmithKline, Ignyta, Janssen, Karyopharm Therapeutics, Roche, Sarcoma Alliance for Research through Collaboration, Threshold Pharmaceuticals, and TRACON Pharma. Steven Attia has received research funding from the Desmoid Tumor Research Foundation, AB Science, TRACON Pharma, CytRx Corporation, Bayer, Novartis, Daiichi Sankyo, Lilly, Immune Design, Karyopharm Therapeutics, Epizyme, Blueprint Medicines, Genmab, CBA Pharma, Merck, Philogen, Gradalis, Deciphera, Takeda, Incyte, Springworks, Adaptimmune, Advenchen Laboratories, Bavarian Nordic, BTG, PTC Therapeutics, GlaxoSmithKline, and FORMA Therapeutics. The other authors have no conflicts of interest to disclose. Publisher Copyright: {\textcopyright} 2020 The Authors and Merck Sharp & Dohme Corp. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2020",
month = jul,
day = "1",
doi = "10.1002/cam4.3039",
language = "English",
volume = "9",
pages = "4593--4602",
journal = "Cancer Medicine",
issn = "2045-7634",
number = "13",
}